10.1093/ajcn/61.6.1402S 28
A commenter stated that the measure duplicates efforts already met through existing standards, such as The Joint Commission's National Patient Safety Goal NPSG.16.01.01Improve Health ( Care Equity
Has Retatrutide Been Approved by the FDA
For these patients, initiating weight loss injections may be considered if: The potential metabolic benefits (improved diabetes control, cardiovascular risk reduction, weight loss) substantially outweigh gallbladder risks Close monitoring is feasible with regular clinical follow-up Patients understand warning signs of gallbladder complications The rate of weight loss can be moderated through dosing strategies Conversely, patients with symptomatic gallstones experiencing biliary colic (right upper quadrant pain after meals), previous episodes of cholecystitis, or complications such as pancreatitisgenerally should undergo evaluation by a gastroenterologist or surgeon before starting weight loss injections
Figure 2: Around half of GLP-1 side effects are gastrointestinal GLP-1s have previously been suggested to be linked to self-harm and suicidal thoughts, but the MHRA concluded in September 2024 that the available data do not support a causal association between GLP-1s and depression, suicidal ideation and suicide, following a review by the European Medicines Agencys pharmacovigilance risk assessment committee 24
When it comes to GLP-1s, this means creating the medication from the base pharmaceutical ingredients
